Page 444 - TBE_Book_V2_2019
P. 444

Chapter 14


                                  Prevention:




               Vaccines and Immunoglobulins



                    Eva-Maria Pöllabauer and Herwig Kollaritsch

          Key Points


           •  Worldwide there are 6 different TBE vaccines – two from Western Europe, three from Russia and
             one from China. The two western European vaccines and one of the Russian vaccines have an adult
             and a pediatric formulation.

           •  The products names are FSME IMMUN and FSME-IMMUN Junior; Encepur adults and Encepur
             children, Klesch-E-Vac,  EnceVir and EnceVir Neo, Dry lyophilized TBE Moscow and Sen Tai Bao

           •  All TBE vaccines except the one from China have similar but not identical immunization sched-
             ules with primary immunization (>3 doses) and regular booster vaccinations. For FSME-IMMUN,
             Encepur and EnceVir a rapid immunization schedules is also licensed. The Chinese vaccine is giv-
             en with 2 primary doses 2 weeks apart followed by annual boosters.

           •  All vaccines induce significant immune responses.  In the absence of a formal correlate of pro-
             tection, the presence of neutralizing antibodies is used as a surrogate marker for protection.


           •  Recent clinical studies show long-term seropersistence of TBE antibodies after the first booster
             vaccination (dose 4) with the two European vaccines.

           •  An effectiveness of approximately 99% (years 2000–2006) and 98,7% (years 2000-2011) was
             calculated for regularly vaccinated persons in Austria, a country with established high vaccina-
             tion uptake.

           •  Whereas in Western Europe post-exposure prophylaxis with immunoglobulins was discontinued
             in the late 1990s, in the highly endemic regions of Russia it continues to be common practice.

           •  Both   FSME-IMMUN and Encepur are well tolerated with a well-established safety profile.
             TBE-Moscow and EnceVir appear to be somewhat more reactogenic.


          Active immunization


          The first generation of tick-borne encephalitis   formulations and growth media were adapted
          (TBE) vaccines was produced in Russia; these   step-by-step  to  result  in  the  currently  used
          vaccines  were  based  on  the  Far  Eastern  TBE   TBE vaccines, details of which are summarized
          virus (TBEV-FE) strain Sofjin, and were mouse-  in Table 1. The 2 so called ‘Western vaccines’
          brain  propagated.  Over  several  decades,   are  FSME-IMMUN,  which  is  licensed  through

                                                  446
                                                  439
   439   440   441   442   443   444   445   446   447   448   449